Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Case ReportCase Report

Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases

Mohan Hingorani, Sanjay Dixit, Pattu Pugazhenthi, Simon Hawkyard, Andrew Robertson and Richard Khafagy
Cancer Biology & Medicine March 2015, 12 (1) 60-63; DOI: https://doi.org/10.7497/j.issn.2095-3941.2014.0025
Mohan Hingorani
1Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mohan.hingorani{at}hey.nhs.uk
Sanjay Dixit
1Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pattu Pugazhenthi
1Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Hawkyard
2Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Robertson
2Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Khafagy
2Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Papatsoris AG,
    2. Karamouzis MV,
    3. Papavassiliou AG.
    Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Curr Med Chem 2005;12:277–296.
    OpenUrlPubMedWeb of Science
  2. 2.
    1. Nemes A,
    2. Tomuleasa C,
    3. Kacso G.
    The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.. J BUON 2014;19:357–364.
    OpenUrl
  3. 3.↵
    1. Mukherji D,
    2. El Dika I,
    3. Temraz S,
    4. Haidar M,
    5. Shamseddine A.
    ShamseddineEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. Ther Clin Risk Manag 2014;10:373–380.
    OpenUrlPubMed
  4. 4.↵
    1. Moser L,
    2. Schubert T,
    3. Hinkelbein W.
    HinkelbeinHormone-refractory and metastatic prostate cancer - palliative radiotherapy. Front Radiat Ther Oncol 2008;41:117–125.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Stamell EF,
    2. Wolchok JD,
    3. Gnjatic S,
    4. Lee NY,
    5. Brownell I.
    The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013;85:293–295.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Finkelstein SE,
    2. Fishman M.
    Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol 2012;2:169.
    OpenUrlPubMed
  7. 7.↵
    1. Ludgate CM.
    Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res 2012;18:4522–4525.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. John-Aryankalayil M,
    2. Palayoor ST,
    3. Cerna D,
    4. Simone CB 2nd.,
    5. Falduto MT,
    6. Magnuson SR, et al.
    Fractionated radiation therapy can induce a molecular profile for therapeutic targeting. Radiat Res 2010;174:446–458.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 12 (1)
Cancer Biology & Medicine
Vol. 12, Issue 1
1 Mar 2015
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases
Mohan Hingorani, Sanjay Dixit, Pattu Pugazhenthi, Simon Hawkyard, Andrew Robertson, Richard Khafagy
Cancer Biology & Medicine Mar 2015, 12 (1) 60-63; DOI: 10.7497/j.issn.2095-3941.2014.0025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases
Mohan Hingorani, Sanjay Dixit, Pattu Pugazhenthi, Simon Hawkyard, Andrew Robertson, Richard Khafagy
Cancer Biology & Medicine Mar 2015, 12 (1) 60-63; DOI: 10.7497/j.issn.2095-3941.2014.0025
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Case reports
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway
  • Extracranial metastasis of anaplastic oligoastrocytoma
  • Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
Show more Case Report

Similar Articles

Keywords

  • Prostate cancer
  • palliative
  • radiotherapy
  • chemotherapy

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire